top of page
At the Pharmacy

Our News

Dreamaderm’s Key Achievements 

ULP-Golden Passport-56 (1).JPG

Dreamaderm's 'Golden Passport Pitch Competition' Achievement

DREAMADERM's participation in the Golden Passport Pitch Competition, a joint initiative by Allergan Aesthetics an AbbVie company and University Lab Partners (ULP), underscores its commitment to aesthetic innovation. Recognized for its potential in the industry, DREAMADERM was among the finalists invited to present at the Demo Day event. This opportunity provided access to key industry mentors and webinars, further enhancing DREAMADERM's visibility and growth in the aesthetics sector.

DREAMADERM Joins Octane’s LaunchPad

Following its presentation at the pitch competition, DREAMADERM successfully established a strategic alliance with Octane, an influential judge at the event. This alliance has placed Dreamaderm within an elite network of industry leaders. Octane, through its LaunchPad SBDC program, has supported over 1,573 companies since its inception in 2010, and its alumni secured a remarkable $5.2 billion in funding.

Proven Process

Octane’s LaunchPad SBDC Offers


Strengthened Capital Funding Strategy


Access to an Influential Network


Actionable Feedback


Proprietary Predictive Analytics


Strategic Mentorship

DREAMADERM's aesthetics technology forum presentation at Balboa Bay Club Newport Beach, CA January 25th, 2024.

Media Interview

Press Releases

Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
February 26, 2024
Pacific Software Inc. (OTC: PFSF) today announced the acquisition of certain business assets of Dreamaderm Inc., a pioneer in dermatological innovation.

Pacific Software Inc. (“PFSF”) acquired certain assets of Dreamaderm Inc. ("Dreamaderm") through a plan of Acquisition, dated January 24, 2024. PFSF will now be the exclusive holder of a patented, first-in- class cosmeceutical asset, branded as Dermatrix. This groundbreaking technology boosts natural collagen production through a novel mechanism of action: preserving insulin within the skin. PFSF believes that Dermatrix will have broad utility for numerous dermatological applications, ranging from cosmetic treatments, to acute and chronic wound care, to advanced medical aesthetics procedures.

Dermatrix prevents the breakdown of insulin by blocking the action of insulin-degrading enzyme (IDE), a peptidase that is abundant within skin. Insulin directly stimulates collagen production, thus Dermatrix has the effect of maximizing the body's own natural collagen-producing processes. By blocking IDE, Dermatrix also maintains the levels of other peptides vital to skin health and repair processes, such as keratinocyte growth and migration. By virtue of these unique properties, Dermatrix is ideal for a considerable variety of products in both the skin care and wound healing sectors.


Dermatrix is the result of over $6 million in research and development conducted over a period of two decades by Dr. Malcolm A. Leissring, chief science officer of Dreamaderm. Dr. Leissring is an award- winning biomedical researcher currently at the University of California, Irvine (UCI) who is a leading expert on the biology and pharmacology of IDE. The research was conducted at prestigious institutes, including Harvard Medical School, The Scripps Research Institute, Mayo Clinic, and UCI, culminating in a cosmeceutical that is ideally suited for topical use. As the assignee of the patent on Dermatrix, the Regents of the University of California will become an equity stakeholder in PFSF.


“We are excited to have acquired these assets of Dreamaderm,” stated Harrysen Mittler, CEO of PFSF. “As a publicly quoted company we expect to access the capital markets in order to implement and accelerate the innovative Dermatrix cosmeceutical technology and commercialize its retail offerings. The technology has the potential to create a new industry category promising significant growth in the cosmetics and skin care sector creating value for shareholders.


In 2023, Dreamaderm was selected as a finalist and invited to exhibit its Dermatrix technology at “Golden Passport Demo Day,” an aesthetics start-up competition program hosted by University Lab Partners and sponsored by Allergan Aesthetics, a division of AbbVie Inc. (ABBV:NYSE). In January 2024, Dreamaderm was selected as one of six presenters at the Aesthetics Technology Forum (ATF), an annual event organized by the business accelerator, Octane OC, which featured a select audience of leading aesthetics and skin care companies, private aesthetics practitioners, as well as accredited investors.


Dr. Leissring, who will become president of PFSF, stated that “the significance of Dermatrix is difficult to overstate, because it represents an exciting new branch of pharmacology with great promise for an incredibly diverse variety of dermatological applications, both in aesthetics and in wound care.”

bottom of page